Key result
Aliskiren treatment effectively prevented the development of albuminuria and glomerulosclerosis in streptozotocin-induced diabetic mice without altering blood glucose or blood pressure.
Why the study?
Does aliskiren ameliorate diabetic nephropathy in a type 1 diabetes mouse model?
Population
Male DBA/2J mice with streptozotocin-induced type 1 diabetes (n=14)
Comparison
Aliskiren 25 mg/kg intraperitoneal injection 3… vs Saline intraperitoneal injection for 16 weeks
Design
Preclinical, randomized into 2 groups
Follow-up
16 weeks
Authors
Loading...
Hypothesis-generating for aliskiren in diabetic nephropathy; should not yet change clinical practice.
Does aliskiren ameliorate diabetic nephropathy in a type 1 diabetes mouse model?
p-value: p=<0.001
Aliskiren ameliorates diabetic renal injury in a type 1 diabetes mouse model through both angiotensin II-dependent and -independent pathways, supporting its potential use in diabetic kidney disease.
Zhang et al. (2012) studied Diabetic nephropathy (n=21). Aliskiren vs. Saline (vehicle) was evaluated on Urinary albumin to creatinine ratio (ACR) and glomerulosclerosis (p=<0.001). Aliskiren treatment effectively prevented the development of albuminuria and glomerulosclerosis in streptozotocin-induced diabetic mice without altering blood glucose or blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: